Literature DB >> 20925198

CD44 is involved in CXCL-12 induced acute myeloid leukemia HL-60 cell polarity.

Liping Zhou1, Xiaolin Guo, B A Jing, Lianshuang Zhao.   

Abstract

CXCL-12 and its receptor CXCR4 participate in breast cancer and melanoma cell metastasis to bone and lymphoid nodes. CD44, as a receptor for hyaluronic acid, is involved in lymphocyte recirculation, homing, adhesion and migration. But the role of CD44 in CXCL-12 induced leukemia cell migration still remains unclear. The present study showed that CXCL-12 stimulation induced the rapid internalization of CXCR4 and facilitated the formation of lamellipodia and uropod in acute leukemia cell line HL-60. CXCL-12 also induced CD44 translocation into the uropod, while CD44 remained evenly distributed on the untreated cell membranes. Results suggest that CD44 participates in CXCL-12 induced cell polarization and subsequent cell migration.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20925198

Source DB:  PubMed          Journal:  Biocell        ISSN： 0327-9545            Impact factor:   1.254


  5 in total

1.  Biomaterial-enabled delivery of SDF-1α at the ventral side of breast cancer cells reveals a crosstalk between cell receptors to promote the invasive phenotype.

Authors:  Xi Qiu Liu; Laure Fourel; Fabien Dalonneau; Rabia Sadir; Salome Leal; Hugues Lortat-Jacob; Marianne Weidenhaupt; Corinne Albiges-Rizo; Catherine Picart
Journal:  Biomaterials       Date:  2017-02-27       Impact factor: 12.479

Review 2.  New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers.

Authors:  Armel Hervé Nwabo Kamdje; Paul Faustin Seke Etet; Lorella Vecchio; Richard Simo Tagne; Jeremie Mbo Amvene; Jean-Marc Muller; Mauro Krampera; Kiven Erique Lukong
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

3.  The development and characterization of SDF1α-elastin-like-peptide nanoparticles for wound healing.

Authors:  Agnes Yeboah; Rick I Cohen; Renea Faulknor; Rene Schloss; Martin L Yarmush; Francois Berthiaume
Journal:  J Control Release       Date:  2016-04-16       Impact factor: 9.776

4.  Knock-down of CD44 regulates endothelial cell differentiation via NFκB-mediated chemokine production.

Authors:  Berit Olofsson; Helena Porsch; Paraskevi Heldin
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.240

5.  Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.

Authors:  Norbert Vey; Jacques Delaunay; Giovanni Martinelli; Walter Fiedler; Emmanuel Raffoux; Thomas Prebet; Carlos Gomez-Roca; Cristina Papayannidis; Maxim Kebenko; Peter Paschka; Randolph Christen; Ernesto Guarin; Ann-Marie Bröske; Monika Baehner; Michael Brewster; Antje-Christine Walz; Francesca Michielin; Valeria Runza; Valerie Meresse; Christian Recher
Journal:  Oncotarget       Date:  2016-05-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.